NCT01704287 | Merck Sharp & Dohme LLC | Malignant Melanoma | November 20, 2012 | Phase 2 |
NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | Lymphoma | May 24, 2013 | Phase 2 |
NCT00023738 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) | Sarcoma | August 2001 | Phase 1|Phase 2 |
NCT00246012 | Centocor, Inc.|Janssen-Cilag Farmaceutica, S.R.L. | Melanoma | May 2005 | Phase 1|Phase 2 |
NCT00813449 | Simcere Pharmaceutical Co., Ltd | Advanced Melanoma|Untreated Patients | August 2008 | Phase 2 |
NCT00002802 | Children´s Hospital Medical Center, Cincinnati|National Cancer Institute (NCI) | Neuroblastoma | July 1990 | Phase 3 |
NCT02190838 | N.N. Petrov National Medical Research Center of Oncology | Melanoma | April 2014 | Phase 2 |
NCT01280565 | AB Science | Metastatic Melanoma | January 2011 | Phase 3 |
NCT04733183 | Philogen S.p.A. | Soft Tissue Sarcoma | August 28, 2020 | Phase 2 |
NCT01974752 | AstraZeneca | Metastatic|Uveal Melanoma | April 2014 | Phase 3 |
NCT03159897 | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | August 1, 2017 | Phase 3 |
NCT00369681 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) | Lymphoma | May 2006 | Phase 2 |
NCT00110994 | Bayer|Amgen | Cancer|Melanoma | April 2005 | Phase 2 |
NCT00395070 | Vical | Metastatic Melanoma | October 2006 | Phase 3 |
NCT00600496 | AstraZeneca | Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer | December 14, 2007 | Phase 1 |
NCT01376713 | Medical University of Vienna | Stage III Melanoma|Stage IV Melanoma | June 2011 | Phase 2 |
NCT00416377 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) | Lymphoma | | Not Applicable |
NCT00003389 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Lymphoma | June 17, 1999 | Phase 3 |
NCT01476410 | Northwestern University|Robert H. Lurie Cancer Center|Seagen Inc. | Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma | November 2011 | Phase 2 |
NCT01164007 | Hoffmann-La Roche | Malignant Melanoma | June 30, 2006 | Phase 2 |
NCT03761095 | PTC Therapeutics | Leiomyosarcoma | March 13, 2019 | Phase 1 |
NCT04638790 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Hodgkin Lymphoma, Adult | February 1, 2020 | Phase 3 |
NCT00412581 | M.D. Anderson Cancer Center|Celgene Corporation | Melanoma | September 2005 | Phase 1 |
NCT02292979 | The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. | Hodgkin Lymphoma | March 2015 | Phase 2 |
NCT00654732 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Classic Hodgkin Lymphoma|Lugano Classification Stage III Hodgkin Lymphoma AJCC v8|Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8 | March 19, 2008 | Phase 2 |
NCT01251107 | Fondazione Michelangelo | Hodgkin Lymphoma | March 2000 | Phase 3 |
NCT00070642 | Pfizer | Carcinoma, Melanoma | December 2003 | Phase 2 |
NCT00025064 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) | Lymphoma | January 2000 | Phase 2 |
NCT00354523 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals | Solid Tumor|Thyroid Cancer | December 2004 | Phase 1|Phase 2 |
NCT00049595 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l´Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group | Lymphoma | August 2002 | Phase 3 |
NCT00002561 | NCIC Clinical Trials Group|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group | Hodgkin Lymphoma | January 25, 1994 | Phase 3 |
NCT03407144 | Merck Sharp & Dohme LLC | Hodgkin Lymphoma | April 9, 2018 | Phase 2 |
NCT00498979 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Stage IV Melanoma | May 2007 | Phase 1 |
NCT00580320 | Virginia Commonwealth University | Melanoma|Soft Tissue Sarcoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Carcinoid Tumors | September 2004 | Phase 1 |
NCT01055522 | Philogen S.p.A.|Eudax S.r.l. | Metastatic Melanoma | June 2008 | Phase 2 |
NCT05269355 | PTC Therapeutics | Leiomyosarcoma | May 23, 2022 | Phase 2|Phase 3 |
NCT03226249 | Northwestern University|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC | Classical Hodgkin Lymphoma|Lymphocyte-Depleted Classical Hodgkin Lymphoma|Lymphocyte-Rich Classical Hodgkin Lymphoma|Mixed Cellularity Classical Hodgkin Lymphoma|Nodular Sclerosis Classical Hodgkin Lymphoma | November 9, 2017 | Phase 2 |
NCT00070343 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) | Melanoma (Skin) | August 2003 | Not Applicable |
NCT00017225 | German Society for Pediatric Oncology and Hematology GPOH gGmbH|National Cancer Institute (NCI) | Neuroblastoma | May 1997 | Phase 2 |
NCT00004010 | Children´s Oncology Group|National Cancer Institute (NCI) | Lymphoma | October 1999 | Phase 2 |
NCT01227889 | GlaxoSmithKline | Cancer | December 23, 2010 | Phase 3 |
NCT00849875 | GlaxoSmithKline | Melanoma | May 26, 2009 | Phase 2 |
NCT00091572 | Merck Sharp & Dohme LLC|European Organisation for Research and Treatment of Cancer - EORTC | Melanoma | October 20, 2004 | Phase 3 |
NCT00516802 | AstraZeneca|KuDOS Pharmaceuticals Limited | Melanoma Neoplasms | January 2007 | Phase 1 |
NCT00089544 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group | Recurrent Adult Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma AJCC v7|Stage II Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7 | June 17, 2004 | Phase 2 |
NCT04200040 | OrienGene Biotechnology Ltd. | Melanoma (Skin) | August 27, 2017 | Phase 2 |
NCT01763164 | Pfizer | Metastatic or Unresectable Cutaneous Melanoma | July 12, 2013 | Phase 3 |
NCT04685616 | University College, London|Takeda|University of Miami|European Organisation for Research and Treatment of Cancer - EORTC|Australasian Leukaemia and Lymphoma Group|Seagen Inc.|Canadian Cancer Trials Group | Hodgkin Lymphoma | April 14, 2022 | Phase 3 |
NCT00864253 | Celgene|University of Arizona | Malignant Melanoma | April 23, 2009 | Phase 3 |
NCT00526318 | German Society for Pediatric Oncology and Hematology GPOH gGmbH|National Cancer Institute (NCI) | Neuroblastoma | January 2007 | Not Applicable |
NCT00837148 | Memorial Sloan Kettering Cancer Center|Bayer | Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor | February 2009 | Phase 2 |
NCT00991250 | SentoClone AB | Malignant Melanoma | October 2009 | Phase 2 |
NCT00822120 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Lymphoma|Nonneoplastic Condition | July 2009 | Phase 2 |
NCT03004833 | University of Cologne | Classical Hodgkin Lymphoma | February 21, 2017 | Phase 2 |
NCT01692691 | Western Regional Medical Center | Melanoma Metastatic | August 2012 | Phase 2 |
NCT03907488 | National Cancer Institute (NCI) | Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma | July 19, 2019 | Phase 3 |
NCT01569204 | University of Cologne | Hodgkin Lymphoma | October 2012 | Phase 2 |
NCT03023124 | Italian Sarcoma Group | Solitary Fibrous Tumors | March 4, 2018 | Phase 2 |
NCT00597038 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb | Metastatic Melanoma | November 2007 | Phase 1|Phase 2 |
NCT00504504 | M.D. Anderson Cancer Center|Genentech, Inc. | Lymphoma | March 2001 | Phase 2 |
NCT00802880 | Washington University School of Medicine | Sarcoma | March 2009 | Phase 2 |
NCT01551459 | The Clatterbridge Cancer Centre NHS Foundation Trust|Cancer Research UK|Pfizer | Metastatic Uveal Melanoma | October 2010 | Phase 2 |
NCT01693068 | EMD Serono|Merck KGaA, Darmstadt, Germany | N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma | December 5, 2012 | Phase 2 |
NCT00000626 | National Institute of Allergy and Infectious Diseases (NIAID)|Amgen | HIV Infections|Hodgkin´s Disease | | Phase 2 |
NCT04221035 | Gustave Roussy, Cancer Campus, Grand Paris | High-Risk Neuroblastoma | November 5, 2019 | Phase 3 |
NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. | HIV-associated Hodgkin Lymphoma | March 2004 | Phase 2 |
NCT02505269 | Massachusetts General Hospital|Seagen Inc. | Hodgkin Lymphoma | August 7, 2015 | Phase 2 |
NCT01712490 | Takeda|Seagen Inc. | Hodgkin Lymphoma | November 9, 2012 | Phase 3 |
NCT00002791 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group | Sarcoma | February 1997 | Phase 2 |
NCT00003027 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|SWOG Cancer Research Network|Cancer and Leukemia Group B | Melanoma (Skin) | November 13, 1997 | Phase 3 |
NCT01771107 | National Cancer Institute (NCI)|The Lymphoma Academic Research Organisation | AIDS-Related Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage IIIA Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|HIV Infection | March 7, 2013 | Phase 1|Phase 2 |
NCT00433459 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg | Lymphoma | January 2007 | Phase 3 |
NCT04727242 | Kristen Ganjoo|Stanford University | LMS - Leiomyosarcoma|Uterine Leiomyosarcoma | January 28, 2021 | Phase 2 |
NCT05987332 | IDEAYA Biosciences | Metastatic Uveal Melanoma | August 31, 2023 | Phase 2|Phase 3 |
NCT01534078 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute|Seagen Inc. | Hodgkin Lymphoma | March 2012 | Phase 2 |
NCT00226473 | Dermatologic Cooperative Oncology Group | Metastatic Melanoma | September 2001 | Phase 4 |
NCT00003421 | Medical Research Council|National Cancer Institute (NCI) | Lymphoma | June 1998 | Phase 3 |
NCT02181738 | Bristol-Myers Squibb | Hodgkin Disease | August 12, 2014 | Phase 2 |
NCT00016263 | Genta Incorporated|National Cancer Institute (NCI) | Melanoma (Skin) | July 2000 | Phase 3 |
NCT05922904 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC|Seagen Inc. | Hodgkin Lymphoma | September 30, 2023 | Phase 2 |
NCT05675410 | National Cancer Institute (NCI) | Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | April 28, 2023 | Phase 3 |
NCT00533702 | Eli Lilly and Company | Metastatic Malignant Melanoma | November 2007 | Phase 2 |
NCT00005090 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B | Lymphoma | April 2000 | Phase 3 |
NCT05404945 | University of Virginia|Merck Sharp & Dohme LLC | Classical Hodgkin Lymphoma | July 26, 2022 | Phase 2 |
NCT01721746 | Bristol-Myers Squibb | Unresectable or Metastatic Melanoma | December 21, 2012 | Phase 3 |
NCT02661503 | University of Cologne | Classical Hodgkin Lymphoma | July 2016 | Phase 3 |
NCT01716806 | Seagen Inc.|Bristol-Myers Squibb | Hodgkin Disease|Peripheral T Cell Lymphoma | October 31, 2012 | Phase 2 |
NCT00324155 | Bristol-Myers Squibb|Medarex | Melanoma | August 2006 | Phase 3 |
NCT01681212 | Bristol-Myers Squibb | Melanoma | October 2012 | Phase 2 |
NCT00678327 | University College, London|Cancer Research UK|Cancer Research UK & UCL Cancer Trials Centre | Lymphoma | August 29, 2008 | Phase 3 |
NCT04893356 | National Cancer Institute, Naples | Sarcoma | January 20, 2021 | |
NCT00072124 | National Cancer Institute (NCI) | Melanoma (Skin) | September 2003 | Phase 3 |
NCT03033914 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Barbara Ann Karmanos Cancer Institute|British Columbia Cancer Agency | Hodgkin Lymphoma | January 25, 2017 | Phase 1|Phase 2 |
NCT01705392 | Haukeland University Hospital|The Norwegian Melanoma Group|Norwegian Cancer Society | Metastatic Malignant Melanoma|Unresectable Malignant Melanoma | January 2013 | Phase 2 |
NCT00033644 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation | Sarcoma | March 2002 | Phase 2 |
NCT01868451 | Memorial Sloan Kettering Cancer Center|Seagen Inc.|University of Rochester|City of Hope Medical Center|Stanford University | Hodgkin Lymphoma | May 2013 | Not Applicable |
NCT00308607 | University of Turku | Metastatic Melanoma | August 2005 | Phase 2 |
NCT00936221 | AstraZeneca | Melanoma | July 2009 | Phase 2 |
NCT01920932 | St. Jude Children´s Research Hospital|Seagen Inc. | Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma | August 12, 2013 | Phase 2 |
NCT00066196 | MedImmune LLC | Melanoma|Malignant Metastatic Melanoma | August 2003 | Phase 2 |
NCT01692678 | Xian-Janssen Pharmaceutical Ltd. | Advanced or Metastatic Liposarcoma or Leiomyosarcoma | August 7, 2012 | Phase 3 |
NCT00003647 | Vical | Stage IV Melanoma|Stage III Melanoma|Recurrent Melanoma | July 1998 | Phase 3 |
NCT03712202 | City of Hope Medical Center|National Cancer Institute (NCI) | Ann Arbor Stage I Hodgkin Lymphoma|Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IA Hodgkin Lymphoma|Ann Arbor Stage IB Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Ann Arbor Stage I Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Mixed Cellularity Classic HL|Ann Arbor Stage II Nodular Sclerosis Classic HL | November 28, 2018 | Phase 2 |
NCT03233347 | Academic and Community Cancer Research United|National Cancer Institute (NCI) | Ann Arbor Stage I Hodgkin Lymphoma|Ann Arbor Stage IA Hodgkin Lymphoma|Ann Arbor Stage IB Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Classic Hodgkin Lymphoma | October 13, 2017 | Phase 2 |
NCT02797717 | GALIA AVRAHAMI|University of Giessen|Rabin Medical Center | Classical Hodgkins Lymphoma in Children and Adolescents. | November 2015 | Not Applicable |
NCT03527628 | King Abdullah International Medical Research Center | Classical Hodgkin Lymphoma|Hodgkin Lymphoma (Category)|Hodgkin Disease|Hodgkin Lymphoma | January 1, 2018 | Phase 2 |
NCT03430297 | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma|Unresectable Melanoma | February 2, 2018 | Phase 3 |
NCT01343277 | Janssen Research & Development, LLC|PharmaMar | Advanced Liposarcoma or Leiomyosarcoma | June 2011 | Phase 3 |
NCT03805022 | Institut Bergonié|Novartis|Chugai Pharma France | Non-metastatic Soft-tissue Sarcoma|Resectable | February 14, 2019 | Phase 3 |
NCT01404936 | M.D. Anderson Cancer Center|Schering-Plough | Lymphoma | July 1996 | Phase 2 |
NCT02979522 | Takeda | Hodgkin Disease | September 6, 2017 | Phase 1|Phase 2 |
NCT00615160 | Michael Weichenthal|University Hospital Schleswig-Holstein | Melanoma | December 2006 | Phase 1|Phase 2 |
NCT03277924 | Grupo Espanol de Investigacion en Sarcomas | Soft Tissue Sarcoma|Bone Sarcoma | May 31, 2017 | Phase 1|Phase 2 |
NCT03646123 | Seagen Inc.|Bristol-Myers Squibb | Hodgkin Lymphoma | January 28, 2019 | Phase 2 |
NCT03070392 | Immunocore Ltd | Uveal Melanoma | October 16, 2017 | Phase 2 |
NCT02545075 | Bristol-Myers Squibb | Melanoma | October 31, 2015 | Phase 3 |
NCT01060904 | Seagen Inc.|Millennium Pharmaceuticals, Inc. | Disease, Hodgkin | January 2010 | Phase 1 |
NCT03517137 | European Organisation for Research and Treatment of Cancer - EORTC | Advanced Hodgkin Lymphoma | August 1, 2019 | Phase 2 |
NCT00796991 | Bristol-Myers Squibb|Medarex | Advanced Melanoma | February 2009 | Phase 1 |
NCT00006200 | National Center for Research Resources (NCRR) | Melanoma | | Phase 2 |
NCT05008224 | Merck Sharp & Dohme LLC | Classical Hodgkin Lymphoma | October 7, 2021 | Phase 2 |
NCT04225390 | University of Erlangen-Nürnberg Medical School|University Hospital Regensburg|Wuerzburg University Hospital | Immunotherapy | January 13, 2020 | Phase 2 |
NCT00779714 | University of Wuerzburg|Hiege-Stiftung gegen Hautkrebs|medac GmbH|DCS Innovative Diagnostik Systeme | Melanoma | October 2008 | Phase 3 |
NCT03279601 | Peking University | Neuroendocrine Tumors | September 1, 2017 | Phase 2 |
NCT02684708 | University of Giessen|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide | Classical Hodgkin Lymphoma | October 1, 2015 | Phase 3 |
NCT00002882 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Melanoma|Skin Cancer | November 1995 | Phase 3 |
NCT00920153 | French Innovative Leukemia Organisation | Lymphoma | May 2008 | Phase 3 |
NCT01614301 | University of Regensburg|ClinAssess GmbH | Advanced Melanoma | May 2012 | Phase 1|Phase 2 |
NCT00004141 | University of Chicago|National Cancer Institute (NCI) | Melanoma (Skin) | August 1998 | Phase 2 |
NCT01327885 | Eisai Inc. | Soft Tissue Sarcoma | March 10, 2011 | Phase 3 |
NCT01152788 | NCIC Clinical Trials Group|Canadian Cancer Trials Group | Melanoma | June 28, 2010 | Phase 2 |
NCT00002669 | European Organisation for Research and Treatment of Cancer - EORTC | Melanoma (Skin) | June 1995 | Phase 2 |
NCT00518895 | Genta Incorporated | Melanoma | July 2007 | Phase 3 |
NCT01132807 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Lymphoma | May 2010 | Phase 2 |
NCT01835145 | National Cancer Institute (NCI)|Exelisis | Recurrent Uveal Melanoma|Stage III Uveal Melanoma AJCC v7|Stage IIIA Uveal Melanoma AJCC v7|Stage IIIB Uveal Melanoma AJCC v7|Stage IIIC Uveal Melanoma AJCC v7|Stage IV Uveal Melanoma AJCC v7 | July 31, 2013 | Phase 2 |
NCT00130442 | Cellxpert Biotechnology Corp.|Medigen Biotechnology Corporation | Melanoma | June 2005 | Phase 2 |
NCT00041210 | Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI) | Lymphoma | October 2001 | Phase 3 |
NCT00553618 | University of Louisville|James Graham Brown Cancer Center | Metastatic Melanoma | August 2007 | Phase 2 |
NCT00911443 | sigma-tau i.f.r. S.p.A. | Malignant Melanoma | July 2002 | Phase 2 |
NCT01006980 | Hoffmann-La Roche | Malignant Melanoma | January 2010 | Phase 3 |
NCT01100528 | Case Comprehensive Cancer Center | Ciliary Body and Choroid Melanoma, Medium+Large Size|Ciliary Body and Choroid Melanoma, Small Size|Iris Melanoma|Recurrent Intraocular Melanoma | November 11, 2009 | Phase 2 |
NCT03016819 | Advenchen Laboratories, LLC | Alveolar Soft Part Sarcoma|Leiomyosarcoma|Synovial Sarcoma|Soft-Tissue Sarcoma | August 15, 2017 | Phase 3 |
NCT04067037 | Henan Cancer Hospital | Classical Hodgkin Lymphoma | August 26, 2019 | Phase 2 |
NCT00416832 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg | Lymphoma | November 2002 | Phase 2 |
NCT03331341 | University of Washington | Classical Hodgkin Lymphoma | January 9, 2019 | Phase 2 |
NCT00006237 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Children´s Oncology Group | Melanoma (Skin) | August 2000 | Phase 3 |
NCT01143402 | National Cancer Institute (NCI) | Iris Melanoma|Medium+Large Size Posterior Uveal Melanoma|Ocular Melanoma With Extraocular Extension|Recurrent Uveal Melanoma|Small Size Posterior Uveal Melanoma|Stage IV Uveal Melanoma | June 2010 | Phase 2 |
NCT01133977 | Eisai Inc.|Quintiles, Inc. | Stage IV Melanoma | April 2010 | Phase 1|Phase 2 |
NCT00559026 | Istituto Superiore di Sanità|Regina Elena Cancer Institute|University of Rome Tor Vergata | Melanoma | September 2004 | Phase 1 |
NCT01542255 | Dartmouth-Hitchcock Medical Center | Metastatic Melanoma | June 2010 | Phase 2 |
NCT01359956 | National Cancer Institute, Naples | Malignant Melanoma|Recurrent Melanoma | April 2002 | Phase 3 |
NCT02298257 | The Lymphoma Academic Research Organisation | HIV Infection|HIV-associated Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma | June 2015 | Phase 2 |
NCT00410631 | German Society for Pediatric Oncology and Hematology GPOH gGmbH|National Cancer Institute (NCI) | Neuroblastoma | October 2004 | Phase 3 |